PlainRecalls
ModerateClass IIOngoing

FDA Drug recall · Reported August 19, 2026

SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-495-05

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

Recall #
D-0747-2026
Affected scope
56,918 vials.
Initiated
July 29, 2026
Verify with FDA Drug →
View my saved recalls

Apollo Care, LLC recalled SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous In… - a moderate-severity action.

SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous In… was recalled by Apollo Care, LLC in August 19, 2026. Reason: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material. Check the official notice for the remedy. Verify recall #D-0747-2026 with the FDA Drug before acting.

The recall

Apollo Care, LLC issued this moderate-severity FDA Drug recall-Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material.

Moderate
severity level
Class II
classification
August 19, 2026
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0747-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-0747-2026) was formally reported on August 19, 2026, with the manufacturer initiating the action on July 29, 2026. It is classified under Moderate severity (Class II), with a current status of Ongoing. Apollo Care, LLC is listed as the recalling firm, operating out of Columbia, MO. Federal records list the affected scope as 56,918 vials..

The documented reason for this recall is: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material Distribution data in the federal record shows the product reached: Nationwide within the U.S. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug and 2 from Apollo Care, LLC - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,472 drugs & medications recalls on record

05001,0001,5002,000 2006201220152018202120242026 448
Severity1906864652High severity (most serious)Moderate severityLow severity
Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-495-05

Reason for recall

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Moderate (Class II)
Status Ongoing
Recall number D-0747-2026
Date reported August 19, 2026
Date initiated July 29, 2026
Recalling firm Apollo Care, LLC
Firm location Columbia, MO
Affected scope 56,918 vials.
Distribution Nationwide within the U.S

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-0747-2026) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-495-05. Recalled by Apollo Care, LLC. Units affected: 56,918 vials..
Why was this product recalled?
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
Which agency issued this recall?
This recall was issued by the FDA Drug on August 19, 2026. Severity: Moderate. Recall number: D-0747-2026.
Where was the recalled product distributed?
Distribution: Nationwide within the U.S.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported August 19, 2026. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026